News | Radiology Business | July 20, 2020

The Industry Mourns the Loss of Sanjiv Sam Gambhir, M.D., Ph.D.

The radiology and molecular imaging fields mourn the loss of another brilliant leader, Sanjiv Sam Gambhir, M.D., Ph.D.

Sanjiv Sam Gambhir, M.D., Ph.D.

July 20, 2020 — The radiology and molecular imaging fields mourn the loss of another brilliant leader. Sanjiv Sam Gambhir, M.D., Ph.D., director of the Molecular Imaging Program at Stanford and the Chairman of the Department of Radiology at Stanford University School of Medicine, has died from cancer at age 57. He is known for his work in early cancer detection and advancing molecular imaging, which is potentially vital in detecting and diagnosing metabolic diseases such as cancer, as well as neurological and cardiovascular diseases.

Gambhir received numerous awards, medals, and honors for his work in advancing Molecular Imaging, Nuclear Medicine, and early cancer detection. Some of his recent honors include the IEEE Marie Sklodowska-Curie Award, IEEE Advancing Technology for Humanity in 2019, and the Distinguished Investigator Award, 7th Annual Academy for Radiology and Biomedical Imaging in 2018. On the day his death was announced, he also received Stanford’s highest honor, the Dean’s Medal for Academic Excellence reserved for those whose scientific, medical, or humanitarian work has advanced the mission of Stanford Medicine, according to a report in Indica News.

Related Content

Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

56-Year-Old Woman With Benign Hemangioma: Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma.

News | Magnetic Resonance Imaging (MRI) | October 16, 2020
October 16, 2020 — 
Mevion Medical Systems announced that it has shipped the accelerator module for the Mevion S250i Proton Therapy System to Kunshan, China. The 15-ton compact accelerator, the heart of the proton therapy system, is the smallest of its kind and will be the first in China.

Mevion's compact accelerator module is lifted and placed on a truck for the first leg of its journey to China. (Photo: Business Wire)

News | Proton Therapy | October 16, 2020
October 16, 2020 — Mevion Medical Systems announced that it has shipped the accelerator module for the...
Carestream Health will offer insights on technology, innovative new products and research in medical imaging through a new webinar series titled Carestream Talks. #RSNA20
News | Radiology Education | October 14, 2020
October 14, 2020 — Carestrea